Tuberculosis (TB) is one of the most common infections in the world. It is estimated that one-third of the world's population is currently infected with TB.1 The majority of those infected have latent tuberculosis (LTBI). Following infection with Mycobacterium tuberculosis (MTB), the organism replicates, most commonly in the lung as the portal of entry, then spreads through lymphatics to the blood stream where virtually any organ in the body can become infected. By the time this has occurred (2-3 months after infection) the host immune response develops in 95% of otherwise healthy persons and sets up granulomas that wall off the MTB organisms wherever they have settled. Many of these organisms remain viable in a dormant or latent state with the potential to reactivate at a later date when the immune system may weaken. The percentage of otherwise healthy persons who eventually reactivate varies from 5% to 15%; the younger the age at initial infection, the higher the risk of reactivation.2 Latent tuberculosis can be effectively treated with a completed course of therapy with either isoniazid or rifampin. Therefore, the Centers for Disease Control and Prevention and the American Thoracic Society have designated the identification and treatment of patients with LTBI as one of the major goals in eliminating TB from the United States.3 It is estimated that 10 to 15 million persons in the United States currently have LTBI.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Pediatrics editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.